Topotecan in the management of cervical cancer

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 2, 2007, Pages 227-236

  Randall Whitis, Leslie M ^a   Monk, Bradley J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Camptothecins; Cervical cancer; Cisplatin; Combination chemotherapy; Topoisomerase I inhibitors; Topotecan

Indexed keywords

CISPLATIN; DNA TOPOISOMERASE; DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IFOSFAMIDE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE; PACLITAXEL; TIRAPAZAMINE; TOPOTECAN; VINBLASTINE; WART VIRUS VACCINE;

ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; HUMAN; KIDNEY CLEARANCE; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; QUALITY OF LIFE; RECURRENT CANCER; REVIEW; SOLID TUMOR; SURVIVAL TIME; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; TOPOTECAN; UTERINE CERVICAL NEOPLASMS;

EID: 33846781385     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.2.227     Document Type: Review

References (65)

1. WALL ME, WANI MC, COOK KH, MCPHAIL AT, SIM GA: Plant antitumour agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukaemia and tumour inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. (1966) 88:3888-3890.
2. HSIANG YH, HERTZBERG R, HECHT S, LIU LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. (1985) 260:14873-14878.
3. HSIANG YH, LIU LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. (1988) 48:1722-1726.
4. JEMAL A, SIEGEL R, WARD E: Cancer Statistics 2006. CA Cancer J. Clin. (2006) 56 (2):106-130.
5. DUPONT N, MONK BJ: Chemotherapy in the management of cervical carcinoma. Clin. Adv. Hematol. Oncol. (2006) 4(4):279-286.
6. KINGSBURY WD, BOEHM JC, JAKAS DR: Synthesis of water-soluble (aminoalkyl) camptothecin analogs. J. Med. Chem. (1991) 34:98-107.
7. FASSBERG J, STELLA, VJ: A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. (1992) 81:676-684.
8. VAN WARMERDAM LJ, CREEMERS GJ, RODENHUIS S et al.: Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in Phase II clinical trials using a limited-sampling procedure. Cancer Chemother. Pharmacol. (1996) 38(3):254-260.
9. HSIANG YH, LIHOU MG, LIU LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. (1989) 49:5077-5082.
10. RAPISARDA A, URANCHIMEG B, SCUDIERO DA et al.: Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. (2002) 62(15):4316-4324.
11. RAPISARDA A, URANCHIMEG B, SORDET O, POMMIER Y, SHOEMAKER RH, MELILLO G: Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. (2004) 64(4):1475-1482.
12. GARCIA-CARBONERO R, SUPKO JG: Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res. (2002) 8(3):641-661.
13. HOKI Y, FUJIMORI A, POMMIER Y: Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother. Pharmacol. (1997) 40:433-438.
14. JONSSEN E, FRIDBORG H, CSOKA K et al.: Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br. J. Cancer. (1997) 76:211-219.
15. SUGIMOTO Y, TSUKAHARA S, OH-HARA T, ISOE T, TSURUO T: Decreased expression of DNA topoisomerase I in camptothecin-resistant tumour cell lines as determined by monoclonal antibody. Cancer Res. (1990) 50:6925-6930.
16. LIEBES L, POTMESIL M, KIM T et al.: Pharmacodynamics of topoisomerase I inhibition: western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies created with topotecan. Clin. Cancer Res. (1998) 4(3):545-557.
17. HOCHSTER H, LIEBES L, SPEYER J et al.: Effect of prolonged topotecan infusion on topoisomerase 1 levels: a Phase I and pharmacodynamic study. Clin. Cancer Res. (1997) 3(8):1245-1252.
18. SCHOEMAKER NE, HERBEN VM, DE JONG LA et al.: Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-to potecan in a Phase I study. Anti-Cancer Drugs. (2002) 13(1):87-91.
19. KAUFMANN SH, GORE SD, LETENDRE L et al.: Factors affecting topotecan sensitivity in human leukaemia samples. Ann. N. Y. Acad. Sci. (1996) 803:128-142.
20. EDER JP, CHAN V, WONG J et al.: Sequence effect of CPT-11 and topoisomerase II inhibitors in vivo. Cancer Chemother. Pharmacol. (1998) 42(4):327-335.
21. VERHAAR-LANGEREIS M, KARAKUS A, VAN EIJKEREN M et al.: Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum resistant ovarian cancer. Int. J. Gynecol. Cancer (2006) 16(1):65-70.
22. SEIDEN MV, NG SW, SUPKO JG et al.: A Phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumours. Clin. Cancer Res. (2002) 8(3):691-697.
23. TAMURA H, KOHCHI C, YAMADA R et al.: Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res. (1991) 19:69-75.
24. RUBIN E, PANTAZIS P, BHARTI A et al.: Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J. Biol. Chem. (1994) 269:2433-2439.
25. POMMIER Y, KERRIGAN D, HARTMAN KD et al.: Phosphorylation of mammalian DNA topoisomerase I and activation by protein kinase C. J. Biol. Chem. (1990) 265:9418-9422.
26. KASID UN, HALLIGAN B, LIU LF et al.: Poly(ADP-ribose)-mediated post-translational modification of chromatin-associated human topoisomerase I. Inhibitory effects on catalytic activity. J. Biol. Chem. (1989) 264:18687-18692.
27. YANG SW, BURGIN AB, HUIZENGA BN et al.: A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and Type I topoisomerases. Proc. Natl. Acad. Sci. USA (1996) 93:11534-11539.
28. MAO Y, SUN M, DESAI SD et al.: SUMO-1 conjugation to topoisomerase I: a possible repair response to topoisomerase-mediated DNA damage. Proc. Natl Acad. Sci. USA (2000) 97:4046-4051.
29. ROWINSKY EK, GROCHOW LB, HENDRICKS CB et al.: Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol. (1992) 10:647-656.
30. ROSING H, HERBEN VMM, VAN GORTEL-VAN ZOMEREN DM et al.: O-glucuronidation a newly identified metabolic pathway for topotecan and N-desmethyl topotecan. Anti-Cancer Drugs (1998) 9:587-592.
31. MI Z, MALAK H, BURKE TG: Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry (1995) 34:13722-13728.
32. O'REILLY S, ROWINSKY EK, SLICHENMYER W et al.: Phase I and pharmacologic study of topotecan in patients with impaired renal function. J. Clin. Oncol. (1996) 14:3062-3073.
33. SCHELLENS JMH, CREEMERS GJ, BEIJNEN JH et al.: Bioavailability and pharmacokinetics of oral topotecan, a new topoisomerase I inhibitor. Br. J. Cancer (1996) 73:1268-1271.
34. TEWARI KS, MONK BJ: Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep. (2005) 7(6):419-434.
35. MUDERSPACH LI, BLESSING JA, LEVENBACK C, MOORE JL JR: A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol. Oncol. (2001) 81(2):213-215.
36. BOOKMAN MA, BLESSING JA, HANJANI P, HERZOG TJ, ANDERSEN WA: Topotecan in squamous cell carcinoma of the cervix: a Phase II study of the Gynecologic Oncology Group. Gynecol. Oncol. (2000) 77(3):446-449.
37. ABU-RUSTUM NR, LEE S, MASSAD LS: Topotecan for recurrent cervical cancer after platinum-based therapy. Int. J. Gynecol. Cancer. (2000) 10(4):285-288.
38. NODA K, SASAKI H, YAMAMOTO K et al.: Phase II trial of topotecan for cervical cancer of the uterus [abstract]. Proceedings of the American Society of Clinical Oncologists. J. Clin. Oncol. (1996) 15:754.
39. DUNTON CJ, KING SA, NEUFELD J et al.: Phase I study of topotecan and radiation therapy in advanced cervical cancer. Gynecol. Oncol. (2002) 85(1):185-187.
40. BELL MC, DAVIDSON SA, MATHIS JM, AMPIL F: Topotecan concomitant with primary brachytherapy radiation in patients with cervical carcinoma: a Phase I trial. Gynecol. Oncol. (2001) 80(2):128-131.
41. LING YH, DONATO NJ, PEREZ-SOLER R: Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines. Cancer Chemother. Pharmacol. (2001) 47(6):473-480.
42. CHAO TC, MOTZER RJ, TONG Y et al.: Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol dcsign. J. Natl Cancer Inst. (1994) 86:1517-1524.
43. ROMANELLI S, PEREGO P, PRATESI G CARENINI N, TORTORETO M, ZUNINO F: In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother. Pharmacol. (1998) 41:385-390.
44. MILLER AA, HARGIS JB, LILENBAUM RC, FIELDS SZ, ROSNER GL, SCHILSKY RL: Phase I study of topotecan and cisplatin in patients with advanced solid tumours: a cancer and leukaemia group B study. J. Clin. Oncol. (1994) 12(12):2743-2750.
45. ROWINSKY EK, KAUFMANN SH, BAKER SD et al.: Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence. J. Clin. Oncol. (1996) 14(12):3074-3084.
46. FIORICA J, HOLLOWAY R, NDUBISI B et al.: Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol. Oncol. (2002) 85(1):89-94.
47. LONG HJ III, BUNDY BN, GRENDYS EC JR et al.: Randomized Phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J. Clin. Oncol. (2005) 23(21):4626-4633.
48. MONK BJ, HUANG HQ, CELLA D, LONG HJ III: Quality of life outcomes from a randomized Phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J. Clin. Oncol. (2005) 23(21):4617-4625.
49. ARMSTRONG DK, O'REILLY S: Clinical guidelines for managing topotecan-related hematologic toxicity. Oncologist (1998) 3:4-10.
50. O'REILLY S, ROWINSKY EK, SLICHENMYER W et al.: Phase I and pharmacologic study of topotecan in patients with impaired hepatic function. J. Natl. Cancer Inst. (1996) 88:817-824.
51. MILLER AA, LILENBAUM RC, LYNCH TJ et al.: Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclicaxel. J. Clin. Oncol. (1996) 14(12):3074-3084.
52. FUJIWARA K, UEOKA H, KIURA K et al.: A Phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer. Cancer Chemother. Pharmacol. (2006) 57(6):755-760.
53. DE JONGE MJ, LOOS WJ, GELDERBLOM H et al.: Phase I pharmacologic study of oral topotecan and intravenous Cisplatin; sequence-dependent hematologic side effects. J. Clin. Oncol. (2000) 18(10):2104-2115.
54. LILENBAUM RC, MILLER AA, BATIST G et al.: Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and Leukaemia Group B study. J. Clin. Oncol. (1998) 16(10):3302-3309.
55. SMITH TJ, KHATCHERESSIAN J, LYMAN GH et al.: 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. (2006) 24(19):3187-3205.
56. GOLD MA, WALKER JL, BEREK JS, HALLUM AV III, GARCIA DJ, ALBERTS DS: Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter Phase III trial in patients with advanced gynecologic malignancies. Gynecol. Oncol. (2003) 90(2):325-330.
57. BONOMI P, BLESSING J, STEHMAN F, DI SAIA P: Randomized trial of three cisplatin dose schedules in schedules in squamous cell carcinoma of the cervix: a gynecologic oncology group study. J. Clin. Oncol. (1985) 3:1079-1085.
58. THIGPEN JT, BLESSING JA, DISAIA PJ, FOWLER WC JR, HATCH KD: A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol. Oncol. (1989) 32(2):198-202.
59. OMURA GA, BLESSING JA, VACCARELLO L et al.: Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. (1997) 15(1):165-171.
60. BLOSS JD, BLESSING JA, BEHRENS BC et al.: Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J. CLin. Oncol. (2002) 20(7):1832-1837.
61. MOORE DH, BLESSING JA, MCQUELLON RP et al.: Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J. Clin. Oncol. (2004) 22(15):3113-3119.
62. KOUTSKY LA, AULT KA, WHEELER CM: A controlled trial of a human papillomavirus Type 16 vaccine. N. Engl. J. Med. (2002) 347(21):1645-1651.
63. BROWN JM, LEMMON MJ: Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumours. Cancer Res. (1990) 50:7745-7749.
64. O'REILLY S, FLEMING GF, BARKER SD et al.: Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. J. Clin. Oncol. (1997) 15(1):177-186.
65. TIERSTEN AD, SELLECK MJ, HERSHMAN DL et al.: Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol. Oncol. (2004) 92(2):635-638.